CN102973559A - Novel method of applying oxymatrine to treating eczematous dermatitis - Google Patents
Novel method of applying oxymatrine to treating eczematous dermatitis Download PDFInfo
- Publication number
- CN102973559A CN102973559A CN2012105079951A CN201210507995A CN102973559A CN 102973559 A CN102973559 A CN 102973559A CN 2012105079951 A CN2012105079951 A CN 2012105079951A CN 201210507995 A CN201210507995 A CN 201210507995A CN 102973559 A CN102973559 A CN 102973559A
- Authority
- CN
- China
- Prior art keywords
- oxymatrine
- eczema
- dermatitis
- treatment
- eczematous dermatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a novel method of applying oxymatrine to treating eczematous dermatitis, belonging to the field of medicines. The method is characterized by 1. adopting intravenous drip of oxymatrine to treat eczematous dermatitis, 2. adopting intravenous drip of oxymatrine to treat eczematous dermatitis in combination with oral administration of antihistamines, 3. adopting oral administration of oxymatrine tablets or capsules to treat eczematous dermatitis and 4. applying oxymatrine ointments to the wounded parts to externally treat eczematous dermatitis. Compared with the existing medicines and methods for treating eczematous dermatitis, the novel method has the effects that unexpected curative effects can be obtained and the cure rate is above 75%. The new method is an innovative idea of holistic treatment for treating eczematous dermatitis and has great medical significance.
Description
?
Technical field
The invention belongs to drug world, particularly relate to the purposes method of Oxymatrine Treating dermatitis, eczema.
Background technology
As everyone knows, dermatitis and eczema is the common disease of department of dermatologry, and the cause of disease of dermatitis and eczema and pathogenesis are not yet clear, and cause of disease very complex is most for allergy causes, it is the allergy that is caused by various internal and external factors interactions.But some dermatitis and eczema is then irrelevant with allergy.The reactive change of patient often relates to many-sided factor, and some is not clear, still remains to be studied from now on.(1) inherited genetic factors: eczema and the heredity of some type have close relationship, and eczema patients often has certain allergic constitution, and the anaphylactic disease medical history is arranged in the family.Easily come in contact the anaphylactic diseases such as dermatitis, drug reaction; (2) environmental factors; The impact of environmental factors mainly refers to increasing and the complex environment allergen; (3) infective agent: some eczema is relevant with the infection of microorganism.These microorganisms comprise that staphylococcus aureus, chlosma, source of the gas fungus such as Alternaria, branch spore are mould, some penicillium sp, Aspergillus fumigatus, reaping hook are mould, Penicllium chrysogenum, aspergillus niger and bread mold etc.; (4) dietary factor: human food variety is extremely many, generally can be divided into plant, animal class, mineral substance, also often uses the food of some chemosynthesis such as glucide, acetic acid, citric acid, essence, synthetic dyestuffs etc. in the food in modern age.These foods can cause the allergy of food, thereby cause the generation of eczema; (5) medicine factor: some medicines can cause eczema and occur; (6) other factors: the generation of eczema still can be brought out eczema or eczema is increased the weight of by weather, physical factors such as the neural Nervous and Mental Factors such as in a depressed state, tired, worried, nervous, excited, insomnia and daylight, ultraviolet, cold, humidity, drying, frictions.The factors such as chronic gastrointestinal diseases, gastrointestinal function obstacle, malnutrition, chronic alcoholism, celiosite and dysbolism, endocrine disturbance all are the reasons that eczema occurs in addition.The extrinsic factor of eczema may be various physicochemical irritations, easily brings out eczema such as Exposure to Sunlight; Cold can make xerosis cutis chap; When hot, the skin hyperhidrosis is easily impregnated, and pruritus and scratching.Use too much soap, cleaning agent etc. in the life, the barrier action of skin is damaged, lose its defencive function, some stimulus object or sensitizer are entered in the body and cause the generation of eczema.Eczema belongs to a kind of delayed allergy, and in pathogenic process, mastocyte plays a part crucial.Mast cell degranulation causes classical immediate allergy on the one hand, eosinophilic granulocyte, chemotactic factor, leukotriene and arachidonic acid thereof by its release row that spreads out is biological etc. again on the other hand, causes again the infiltration of polymorphonuclear cell after 4-8 hour at the position of originally taking off granular cell; After 24-48 hour, polymorphonuclear cell is progressively replaced its infiltration by the inhibitive factor of its release again by monocyte infiltration, and infiltrate the common delayed allergy that forms with macrophage and fibroblast, cause tissue injury that the irritability of mucosa is improved, easily specificity and nonspecific stimulation are reacted, cause the repeatedly outbreak of eczema.
At present, dermatitis and eczema be there is no good method, common Therapeutic Method has following several:
1, base therapy: (1) is avoided bringing out and Acute aggravated factors; (2) recovery and maintenance skin barrier function.2, Drug therapy cooperates topical therapeutic: (1) glucocorticoid: local interruption external glucocorticoid, and cooperate skin moistening wetting agent etc., be the common therapy for the treatment of at present dermatitis and eczema.Life-time service can cause certain skin adverse reaction (such as atrophoderma, telangiectasis, striae distensae, hirsutism, patients with glucocorticoid acne, antibacterial infection, purpura etc.), and long-term large-area applications also can cause systemic untoward reaction (iatrogenic Adrenal cortex function insufficiency, hypercortisolism, Spirit nerve symptoms of disease, glaucoma, cataract and the confusion of the menstrual cycle etc.) sometimes.(2) calcineurin inhibitor: this type of medicine comprises tacrolimus ointment and pimecrolimus emulsifiable paste, and dermatitis and eczema is had good efficacy, has stronger selectivity antiinflammatory action, can be used for relatively for a long time all site of pathological change.Untoward reaction mainly is the burning and excitement of local short time after the medication, not yet finds the untoward reaction of obvious system, also without the untoward reaction of glucocorticoid.(3) topical antibiotic preparation: because antibacterial or fungus can be by producing superantigen or bringing out or increase the weight of the state of an illness as allergen, when using glucocorticoid, when especially treatment has exudative skin lesion, add in early days with antibacterium or antifungal drug and can be conducive to control the state of an illness, but should avoid life-time service.(4) pruritus: 5 % Doxepin Hydrochloride Cream in Animals or the non-body anti-inflammatory drug that stays can alleviate the rash symptom of itching in a short time effectively, can be used alternatingly with Donisolone or calcineurin inhibitor.(5) other: according to the difference of the cleer and peaceful skin lesion of disease, can select soak, zinc oxid oil (paste) agent, tar, Pityrol etc.3, Drug therapy coupled system treatment: (1) antihistaminic and cell membrane stability agent: can select the first generation or second filial generation antihistaminic according to the different state of an illness and medication object.(2) anti-infectives: for disease clear serious (person of oozing out is particularly arranged) or confirmed the patient of secondary antibacterial or fungal infection, but short-term gives anti-infectives.(3) glucocorticoid: can give middle low dose of short-term medication to the patient who is in a bad way.In time gradually decrement, drug withdrawal after sb.'s illness took a favorable turn is in order to avoid the too fast and pathogenic feelings knock-on of the untoward reaction that life-time service brings or drug withdrawal.(4) allergen specific desensitization therapy: be with major antigen material unescapable and that confirm or suspect through skin test or additive method, make certain density leachate, inject with the method for ascending-dose and concentration gradually, by repeatedly giving the patient injection specific antigen, impel to produce corresponding antibody in the body.(5) immunosuppressant: the uppity patient of routine treatment for being in a bad way. can take the circumstances into consideration to select cyclosporin A, azathioprine and Mycophenolate Mofetil etc.(6) Leukotriene modifiers: can be divided into leukotriene antagonist (LTAA) and leukotriene inhibitors.By the antagonism to the cell surface leukotriene receptor, sensitization and the proinflammatory effect of the cysteamine acyl leukotriene that inhibition mastocyte and acidophil discharge.(7) other: tranilast, glycyrrhizic acid and compound vitamin etc. can be selected the treatment for dermatitis and eczema, and the auxiliary therapeutic action interferon-γ is arranged, and being used for that dermatitis and eczema treats may be effectively, but often needs longer-term to keep medication.4, Chinese traditional treatment: according to clinical symptoms and sign, carry out tcm treatment according to syndrome differentiation.5, naturopathy: ultraviolet, phototherapy.Above-mentioned Therapeutic Method is a lot, but its limitation and untoward reaction are arranged, long-term external can cause certain skin adverse reaction (such as atrophoderma, telangiectasis, striae distensae, hirsutism, patients with glucocorticoid acne, antibacterial infection, purpura etc.) such as glucocorticoid, long-term large tracts of land external or orally cause systemic untoward reaction (iatrogenic Adrenal cortex function insufficiency, hypercortisolism, Spirit nerve symptoms of disease, glaucoma, cataract and the confusion of the menstrual cycle etc.).
Because the dermatitis and eczema cause of disease is complicated, although Therapeutic Method is a lot, its limitation and untoward reaction is arranged, therapeutic effect neither be very desirable.
Summary of the invention
Purpose of the present invention will solve the defectives such as existing medicine and method treatment dermatitis and eczema poor effect, side effect are large exactly, and a kind of new purposes method of Oxymatrine Treating dermatitis and eczema that adopts is provided.
Matrine has direct antiinflammatory action, immunoregulation effect, inhibition tumor proliferation, induce differentiation and apoptotic effect, anti-virus sterilizing effect, anti-hypoxia, expansion blood vessel, blood fat reducing, arrhythmia, calmness, analgesic, lower the temperature, improve the hemorheological indexes effect.Oxymatrine (oxymatrine, OMT) be a kind of alkaloid that extracts the Special Traditional Chinese Medicine material-cassia leguminous plant Herba Sophorae alopecuroidis (Sophore alopecuroides. L) from Ningxia Hui Autonomous Region, oxymatrine has multiple pharmacologically active, and safety range is large, toxicity is little, absorbing better, is more widely tcm product of a kind of application prospect.Oxymatrine have direct antiinflammatory antiallergic action, immunoregulation effect, anti-virus sterilizing effect, anti-hypoxia, expansion blood vessel, blood fat reducing, arrhythmia, calmness, analgesic, lower the temperature, improve the hemorheological indexes effect.The direct antiinflammatory of oxymatrine, anti-allergy action: matrine is hormone-like effect to be arranged and without the powerful anti-inflammatory agent of hormone side effect, studies have shown that main with its inhibition leukoplania, stablize lysosome membrane, promote free radical scavenging, the synthetic or release and the inhibition inflammatory activity that suppress the inflammatory mediators such as histamine and lymphokine be relevant; The immunoregulation effect of oxymatrine: oxymatrine has stronger immunoregulation effect, can bring into play its antiinflammatory action by the impact on variation, cytokine and other inflammatory regulatory factor of host's antibody horizontal, immunocyte; The anti-virus sterilizing effect of oxymatrine: it is active that oxymatrine has direct anti-virus sterilizing, and fungicidal spectrum is wider; The central nervous system: oxymatrine has the effect of calmness, analgesia, analgesic, cooling; Digestive system: have the anti-liver injury effect, effectively protect hepatocyte; Oxymatrine has antitumor action: the propagation of energy establishment HepG2 cell lines, and have direct killing effect; Cardiovascular system, oxymatrine have anti-hypoxia, expand the effects such as blood vessel, blood fat reducing, arrhythmia.Antitumor mechanism: oxymatrine has the inhibition tumor proliferation, induces differentiation and apoptotic effect.Based on more than, for the etiology and pathogenesis of dermatitis and eczema morbidity, the direct antiinflammatory of oxymatrine, anti-allergy action can suppress the dermatitis and eczema inflammatory reaction and suppress anaphylaxis; The anti-virus sterilizing effect can be treated the dermatitis and eczema that causes by infecting; The reaction of oxymatrine immunity-regulating; Oxymatrine has the effect of calmness, analgesia, analgesic, cooling the central nervous system, the dermatitis and eczema that scalable is caused by neural Nervous and Mental Factors, and reach antipruritic effect.Therefore oxymatrine has good application prospect as a kind of potential treatment dermatitis and eczema medicine.
The present invention uses oxymatrine to treat dermatitis and eczema by the mode of oral, intravenous drip and external.Concrete technical solution of the present invention is: the one, adopt oxymatrine intravenous drip treatment; The 2nd, adopt oxymatrine capsules or tablet oral medication; The 3rd, adopt oxymatrine ointment to smear affected part external curing dermatitis and eczema.
The present invention has following remarkable result:
1, dermatitis and eczema is dermatology common disease, because it is pathogenic to be that internal and external factor mixes, adopts existing Therapeutic Method effect undesirable.Oxymatrine has antiinflammatory, antiallergic action, immunomodulating, anti-virus sterilizing, calmness, antipruritic, analgesic, the effects such as cooling are treated for the dermatitis and eczema etiology and pathogenesis and to be impelled skin lesion to recover, and comprehensive each organ of balance the body, cardiovascular and cerebrovascular vessel, digestive system disease, metabolic disease are had regulating action, fundamentally solve the radical cure of dermatitis and eczema.
2, the present invention adopts the new purposes of Oxymatrine Treating dermatitis and eczema, owing to adopt the wholistic therapy theory, compare with existing medicine, method and can obtain beyond thought curative effect, cure rate reaches more than 75%, and this new purposes is an innovation to the treatment dermatitis and eczema.
3, Oxymatrine Treating dermatitis and eczema safety range is large, and toxicity is little, fundamentally reverses the pathomechanism of dermatitis and eczema, prevents that complication from occuring, thereby reaches the optimal treatment boundary for the treatment of both the principal and secondary aspects of a disease.
The specific embodiment
Embodiment 1
1 data and method
1.1 clinical data: select 60 routine universal eczema patients, clinical diagnosis meets acute eczema, subacute eczema or chronic eczema acute attack, age 18-68 year, do not accepted treatment in January, without serious viscera diseases such as hepatic and renal function injure, without active tuberculosis, hypertension, diabetes, cataract medical history, reject trimester of pregnancy, women breast-feeding their children.The patient is divided into two groups at random: treatment group 30 examples; Matched group 30 examples.Two groups of equal no difference of science of statistics (P ﹥ 0.05) on age, sex, the course of disease, coincident with severity degree of condition.
1.2 Therapeutic Method treatment group intravenous drip Oxymatrine Injection (0.6g100ml)/d, simultaneously oral antihistamines loratadine; The oral loratadine of matched group.For have obviously ooze out all give 3% boric acid solution soak affected part, every day 2 times, all take 2 weeks as a course for the treatment of, carry out efficacy determination after finishing after the course for the treatment of.Respectively at after first visit same day and two weeks for the treatment of patient's sings and symptoms being observed (comprise pruritus, erythema, pimple, ooze out, rotten to the corn, infiltration or lichenization, keratinization desquamation etc.), each index is all undertaken by 4 grades of point systems when each assessment: 0=without, 1=is slight, 2=moderate, 3=severe.Make scoring, Estimating curative effect, and observe side effect.
1.3 the standard of curative effect evaluation: the integrated value computing formula is: integrated value=(first visit day the integration integration that adds up to ﹣ to treat after 2 weeks add up to)/first visit day integration add up to * 100%.Cure: integrated value reduces＞95%; Produce effects: integrated value reduces 61%-95%; Take a turn for the better: integrated value reduces 20 ~ 60%; Integrated value reduces＜20%.
1.4 two groups of safety evaluatios all with treatment before, check hematuria conventional, biochemical conventional (comprise hepatic and renal function, blood glucose, electrolyte and blood fat) after finishing each course for the treatment of, and the untoward reaction that occurs during the record treatment, occur serious adverse reaction withdraw from the observer be judged to invalid.
1.5 statistical method: adopt SPSSl0.0 statistics software, measurement data adopts the t check, and ranked data adopt Ridit to analyze.
2 results
2.1 two groups of curative effects are relatively: recovery from illness 8 examples (26.67%), produce effects 15 examples (50%), take a turn for the better 5 examples (16.67%), invalid 3 examples (10%) in treatment group 30 examples, effective percentage is 76.67%; Recovery from illness 2 examples (6.67%), produce effects 7 examples (23.33%), take a turn for the better 13 examples (43.33%), invalid 8 examples (26.67%) in matched group 30 examples, effective percentage is 30%.The treatment group cure rate has significant difference (P＜0.01) apparently higher than matched group.
2.2 symptom integral relatively before and after two groups of treatments: the integration for the treatment of group and matched group was respectively 11.04 ± 3.43 minutes and 10.57 ± 3.26 minutes before the treatment, the integration for the treatment of group and matched group was respectively 0.38 ± 0.67 minute and 1.32 ± 1.87 minutes after the treatment, relatively and after treating between group significant difference (P＜0.01) was arranged relatively before and after two groups of group internal therapies.
2.3 untoward reaction: two groups of hematuria biochemics routines are showed no significantly unusually before and after the treatment, have no the untoward reaction of obvious system and occur.
Embodiment 2
Select 30 routine eczema patients, adopt oxymatrine (0.4g100ml)/d, 2 weeks were a course for the treatment of, carried out efficacy determination after finishing after the course for the treatment of.Through statistical procedures, the result shows that Oxymatrine Treating eczema has significant curative effect, has no simultaneously obvious adverse reaction.
Embodiment 3
Select 30 routine eczema patients, adopt oxymatrine capsules (300mg tid po), 2 weeks were a course for the treatment of, carried out efficacy determination after finishing after the course for the treatment of.Through statistical procedures, the result shows that Oxymatrine Treating eczema has significant curative effect, has no simultaneously obvious adverse reaction.
Embodiment 4
Select 30 routine eczema patients, adopt oxymatrine sheet (300mg tid po), 2 weeks were a course for the treatment of, carried out efficacy determination after finishing after the course for the treatment of.Through statistical procedures, the result shows that Oxymatrine Treating eczema has significant curative effect, has no simultaneously obvious adverse reaction.
Embodiment 5
Select 30 routine eczema patients, adopt oxymatrine ointment to be coated with the skin lesion treatment outward, 2 weeks were a course for the treatment of, carried out efficacy determination after finishing after the course for the treatment of.Through statistical procedures, the result shows that Oxymatrine Treating eczema has significant curative effect, has no simultaneously obvious adverse reaction.
Claims (6)
1. the purposes method that the Oxymatrine Treating dermatitis and eczema is new is characterized in that using oxymatrine effectively to treat dermatitis and eczema by oral, intravenous drip and external.
2. the new purposes method of Oxymatrine Treating dermatitis and eczema according to claim 1 is characterized in that adopting oxymatrine intravenous drip treatment dermatitis and eczema, oxymatrine dosage 0.4-0.6g/d, and 2 weeks were a course for the treatment of.
3. the new purposes method of Oxymatrine Treating dermatitis and eczema according to claim 1 is characterized in that adopting the oxymatrine intravenous drip, oxymatrine dosage 0.4-0.6g/d, and while oral antihistamines partner treatment, 2 weeks were a course for the treatment of.
4. the new purposes method of Oxymatrine Treating dermatitis and eczema according to claim 1 is characterized in that adopting the oxymatrine capsules oral medication, and 2 weeks were a course for the treatment of.
5. the new purposes method of Oxymatrine Treating dermatitis and eczema according to claim 1 is characterized in that adopting oxymatrine sheet oral medication, and 2 weeks were a course for the treatment of.
6. the new purposes method of Oxymatrine Treating dermatitis and eczema according to claim 1 is characterized in that adopting oxymatrine ointment to smear affected part external curing dermatitis and eczema.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105079951A CN102973559A (en) | 2012-12-03 | 2012-12-03 | Novel method of applying oxymatrine to treating eczematous dermatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105079951A CN102973559A (en) | 2012-12-03 | 2012-12-03 | Novel method of applying oxymatrine to treating eczematous dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102973559A true CN102973559A (en) | 2013-03-20 |
Family
ID=47848095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012105079951A Pending CN102973559A (en) | 2012-12-03 | 2012-12-03 | Novel method of applying oxymatrine to treating eczematous dermatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102973559A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106266453A (en) * | 2016-08-31 | 2017-01-04 | 郑向东 | A kind of composition for external application and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772406A (en) * | 2012-08-23 | 2012-11-14 | 施惠娟 | Novel application method of treating psoriasis by matrine |
-
2012
- 2012-12-03 CN CN2012105079951A patent/CN102973559A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772406A (en) * | 2012-08-23 | 2012-11-14 | 施惠娟 | Novel application method of treating psoriasis by matrine |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106266453A (en) * | 2016-08-31 | 2017-01-04 | 郑向东 | A kind of composition for external application and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102973560A (en) | Novel method of applying matrine to treating eczematous dermatitis | |
| Meng et al. | Psoriasis therapy by Chinese medicine and modern agents | |
| RU2671492C2 (en) | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders | |
| CN101361790A (en) | Medicine for treating dermatitis eczema, pruritus due to mosquito bites and use thereof | |
| Lee et al. | Synergistic effect of natural compounds on the fatty acid-induced autophagy of activated hepatic stellate cells | |
| WO2018068566A1 (en) | Application of albiflorin in production of products for improving function of intestinal flora system | |
| Long et al. | Clinical observation on the treatment of chronic urticaria with total glucosides of paeony capsule combined with citirizine | |
| Wu et al. | Magnoflorine from Coptis chinese has the potential to treat DNCB-induced Atopic dermatits by inhibiting apoptosis of keratinocyte | |
| CN101829130A (en) | Compound resveratrol anti-inflammatory and itching relieving medicament combination and purpose thereof | |
| CN103285155A (en) | Traditional Chinese medicine composition for treating eczema and dermatitis | |
| WO2019227764A1 (en) | Novel use of mln 4924 in preparation of drug used for treating diabetes and/or obesity | |
| CN105582003A (en) | Application of methyl ferulic acid in preparation of medicine for preventing and treating alcoholic liver disease | |
| CN104672293A (en) | Pentacyclic triterpene structure modified compound as well as preparation method and application thereof | |
| He et al. | Network pharmacology unveils spleen-fortifying effect of Codonopsis Radix on different gastric diseases based on theory of “same treatment for different diseases” in traditional Chinese medicine | |
| CN102973559A (en) | Novel method of applying oxymatrine to treating eczematous dermatitis | |
| Liu et al. | Scorpio and Scolopendra attenuate inflammation and articular damage in rats with collagen-induced arthritis | |
| Liang et al. | Neobavaisoflavone inhibits allergic inflammatory responses by suppressing mast cell activation | |
| CN104161763B (en) | A kind of pharmaceutical composition is as preparing the application treated in dermatitis and eczema | |
| CN101829182B (en) | Medicament for treating prostatic diseases | |
| CN102772406B (en) | Novel application method of treating psoriasis by oxymatrine | |
| Zhang et al. | Effect of Chinese herbal medicine combined with acitretin capsule in treating psoriasis of blood-heat syndrome type | |
| CN114712376A (en) | Application of pulsatilla chinensis saponin B4 in preparation of external-use medicine for treating psoriasis | |
| CN103157050B (en) | Traditional Chinese medicine composition for treating vulvar itching diseases and preparation method thereof | |
| CN102772405A (en) | Novel application method of treating psoriasis by matrine | |
| CN103920076A (en) | Traditional Chinese medicine for treating tinea of feet and hands as well as eczema |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130320 |